GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity.
Saved in:
| Title: | GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. |
|---|---|
| Authors: | Watson DC; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Cleveland, OH, USA.; University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; School of Medicine, Case Western Reserve University, Cleveland, OH, USA.; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Bayik D; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Cleveland, OH, USA.; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Storevik S; Department of Biomedicine, University of Bergen, Bergen, Norway.; Department of Neurology, Haukeland University Hospital, Bergen, Norway., Moreino SS; Department of Biomedicine, University of Bergen, Bergen, Norway., Sprowls SA; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Han J; Department of Biomedicine, University of Bergen, Bergen, Norway., Augustsson MT; Department of Biomedicine, University of Bergen, Bergen, Norway., Lauko A; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.; Medical Scientist Training Program, Case Western Reserve University, Cleveland, OH, USA., Sravya P; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA., Røsland GV; Department of Biomedicine, University of Bergen, Bergen, Norway., Troike K; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Tronstad KJ; Department of Biomedicine, University of Bergen, Bergen, Norway., Wang S; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Sarnow K; Department of Biomedicine, University of Bergen, Bergen, Norway., Kay K; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Lunavat TR; Department of Biomedicine, University of Bergen, Bergen, Norway.; Department of Neurology, Molecular Neurogenetics Unit-West, Massachusetts General Hospital, Boston, MA, USA., Silver DJ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Dayal S; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Joseph JV; Stipe Therapeutics, Aarhus, Denmark., Mulkearns-Hubert E; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA., Ystaas LAR; Department of Biomedicine, University of Bergen, Bergen, Norway., Deshpande G; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Guyon J; University of Bordeaux, INSERM, BRIC, Pessac, France., Zhou Y; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Magaut CR; University of Bordeaux, INSERM, BRIC, Pessac, France., Seder J; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Neises L; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg., Williford SE; University of Alabama at Birmingham, Birmingham, AL, USA., Meiser J; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg., Scott AJ; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Sajjakulnukit P; Cancer Biology Graduate Program, University of Michigan, Ann Arbor, MI, USA., Mears JA; Case Comprehensive Cancer Center, Cleveland, OH, USA.; School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Bjerkvig R; Department of Biomedicine, University of Bergen, Bergen, Norway.; NorLux Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg., Chakraborty A; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Cleveland, OH, USA., Daubon T; University of Bordeaux, CNRS, IBGC, Bordeaux, France., Cheng F; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Cleveland, OH, USA., Lyssiotis CA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.; Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA., Wahl DR; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Hjelmeland AB; University of Alabama at Birmingham, Birmingham, AL, USA., Hossain JA; Department of Biomedicine, University of Bergen, Bergen, Norway., Miletic H; Department of Biomedicine, University of Bergen, Bergen, Norway. hrvoje.miletic@uib.no.; Department of Pathology, Haukeland University Hospital, Bergen, Norway. hrvoje.miletic@uib.no., Lathia JD; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. lathiaj@ccf.org.; Case Comprehensive Cancer Center, Cleveland, OH, USA. lathiaj@ccf.org.; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA. lathiaj@ccf.org. |
| Source: | Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 648-664. Date of Electronic Publication: 2023 May 11. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
